{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:45:00Z","timestamp":1793051100334,"version":"4.5.0"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T00:00:00Z","timestamp":1673481600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012813","name":"MOST","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012813","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001869","name":"Academia Sinica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001869","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["107-2320-B-001-004-MY3"],"award-info":[{"award-number":["107-2320-B-001-004-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.jconrel.2023.01.021","type":"journal-article","created":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T13:47:32Z","timestamp":1673963252000},"page":"354-367","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Accelerated clearance by antibodies against methoxy PEG depends on pegylation architecture"],"prefix":"10.1016","volume":"354","author":[{"given":"Yi-Chen","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing-Mae","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trieu Thi My","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tien-Ching","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talal Salem","family":"Al-Qaisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve R.","family":"Roffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2023.01.021_bb0005","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2165\/00003088-200140070-00005","article-title":"Pegylation: a novel process for modifying pharmacokinetics","volume":"40","author":"Harris","year":"2001","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jconrel.2023.01.021_bb0010","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S1359-6446(05)03575-0","article-title":"PEGylation, successful approach to drug delivery","volume":"10","author":"Veronese","year":"2005","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2023.01.021_bb0015","series-title":"PEGylated Protein Drugs: Basic Science and Clinical Applications","first-page":"11","article-title":"Protein PEGylation, basic science and biological applications","author":"Veronese","year":"2009"},{"key":"10.1016\/j.jconrel.2023.01.021_bb0020","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/wnan.1339","article-title":"Anti-PEG immunity: emergence, characteristics, and unaddressed questions","volume":"7","author":"Yang","year":"2015","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"10.1016\/j.jconrel.2023.01.021_bb0025","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1039\/c1py00034a","article-title":"FDA-approved poly(ethylene glycol)\u2013protein conjugate drugs","volume":"2","author":"Alconcel","year":"2011","journal-title":"Polym. Chem."},{"key":"10.1016\/j.jconrel.2023.01.021_bb0030","series-title":"Polymer-Protein Conjugates","first-page":"3","article-title":"1 - evolution of polymer conjugation to proteins","author":"Zalipsky","year":"2020"},{"key":"10.1016\/j.jconrel.2023.01.021_bb0035","doi-asserted-by":"crossref","first-page":"14022","DOI":"10.1021\/acsnano.1c05922","article-title":"Polyethylene glycol immunogenicity: theoretical, clinical, and practical aspects of anti-polyethylene glycol antibodies","volume":"15","author":"Chen","year":"2021","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2023.01.021_bb0040","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/14728214.2019.1604684","article-title":"Emerging PEGylated non-biologic drugs","volume":"24","author":"Park","year":"2019","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1016\/j.jconrel.2023.01.021_bb0045","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000233309","article-title":"Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins","volume":"70","author":"Richter","year":"1983","journal-title":"Int Arch Allergy Appl Immunol"},{"key":"10.1016\/j.jconrel.2023.01.021_bb0050","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/0192-0561(85)90158-4","article-title":"Studies on antigenicity of the polyethylene glycol (PEG)-modified uricase","volume":"7","author":"Tsuji","year":"1985","journal-title":"Int. J. Immunopharmacol."},{"key":"10.1016\/j.jconrel.2023.01.021_bb0055","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1021\/bc980143z","article-title":"Accelerated clearance of polyethylene glycol-modified proteins by anti-polyethylene glycol IgM","volume":"10","author":"Cheng","year":"1999","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2023.01.021_bb0060","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1021\/bc990147j","article-title":"Efficient clearance of poly(ethylene glycol)-modified immunoenzyme with anti-PEG monoclonal antibody for prodrug cancer therapy","volume":"11","author":"Cheng","year":"2000","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2023.01.021_bb0065","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1021\/bc050133f","article-title":"Monoclonal antibody-based quantitation of poly(ethylene glycol)-derivatized proteins, liposomes, and nanoparticles","volume":"16","author":"Cheng","year":"2005","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2023.01.021_bb0070","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1021\/bc200551b","article-title":"Role of the methoxy group in immune responses to mPEG-protein conjugates","volume":"23","author":"Sherman","year":"2012","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2023.01.021_bb0075","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.molimm.2013.07.014","article-title":"Selectivity of binding of PEGs and PEG-like oligomers to anti-PEG antibodies induced by methoxyPEG-proteins","volume":"57","author":"Saifer","year":"2014","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.jconrel.2023.01.021_bb0080","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12010015","article-title":"Both IgM and IgG antibodies against polyethylene glycol can alter the biological activity of methoxy polyethylene glycol-epoetin beta in mice","volume":"12","author":"Chang","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2023.01.021_bb0085","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1046\/j.1365-2141.2000.02187.x","article-title":"Pegylated asparaginase (Oncaspar) in children with ALL: drug monitoring in reinduction according to the ALL\/NHL-BFM 95 protocols","volume":"110","author":"M\u00fcller","year":"2000","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jconrel.2023.01.021_bb0090","doi-asserted-by":"crossref","first-page":"R12","DOI":"10.1186\/ar1861","article-title":"Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase","volume":"8","author":"Ganson","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jconrel.2023.01.021_bb0095","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/cncr.22739","article-title":"Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients","volume":"110","author":"Armstrong","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.jconrel.2023.01.021_bb0100","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/art.22403","article-title":"Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout","volume":"56","author":"Sundy","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jconrel.2023.01.021_bb0105","doi-asserted-by":"crossref","first-page":"R60","DOI":"10.1186\/ar4497","article-title":"Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout","volume":"16","author":"Lipsky","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jconrel.2023.01.021_bb0110","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pbc.25319","article-title":"PEG-asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHO ALL2008 protocol","volume":"62","author":"Henriksen","year":"2015","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.jconrel.2023.01.021_bb0115","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/j.jaci.2016.04.058","article-title":"Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer","volume":"138","author":"Povsic","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jconrel.2023.01.021_bb0120","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.jaci.2015.10.034","article-title":"Pre-existing anti-polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer","volume":"137","author":"Ganson","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jconrel.2023.01.021_bb0125","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26873","article-title":"Outcome of pediatric patients with acute lymphoblastic leukemia\/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: a report from the Children\u2019s Oncology Group","volume":"65","author":"Rau","year":"2018","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.jconrel.2023.01.021_bb0130","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.chembiol.2019.02.001","article-title":"Anti-PEG antibodies inhibit the anticoagulant activity of PEGylated aptamers","volume":"26","author":"Moreno","year":"2019","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.jconrel.2023.01.021_bb0135","doi-asserted-by":"crossref","first-page":"10661","DOI":"10.1021\/acs.analchem.6b03109","article-title":"Measurement of pre-existing IgG and IgM antibodies against polyethylene glycol in healthy individuals","volume":"88","author":"Chen","year":"2016","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jconrel.2023.01.021_bb0140","doi-asserted-by":"crossref","first-page":"11804","DOI":"10.1021\/acs.analchem.6b03437","article-title":"Analysis of pre-existing IgG and IgM antibodies against polyethylene glycol (PEG) in the general population","volume":"88","author":"Yang","year":"2016","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jconrel.2023.01.021_bb0145","series-title":"Polymer Conjugates With Decreased Antigenicity, Methods Of Preparation And Uses Thereof","author":"Martinez","year":"2004"},{"key":"10.1016\/j.jconrel.2023.01.021_bb0150","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s42004-022-00709-0","article-title":"Structural determination of an antibody that specifically recognizes polyethylene glycol with a terminal methoxy group","volume":"5","author":"Nguyen","year":"2022","journal-title":"Communications Chemistry"},{"key":"10.1016\/j.jconrel.2023.01.021_bb0155","doi-asserted-by":"crossref","first-page":"9930","DOI":"10.1016\/j.biomaterials.2014.08.032","article-title":"One-step mixing with humanized anti-mPEG bispecific antibody enhances tumor accumulation and therapeutic efficacy of mPEGylated nanoparticles","volume":"35","author":"Kao","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2023.01.021_bb0160","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejpb.2018.02.019","article-title":"A hydroxyl PEG version of PEGylated liposomes and its impact on anti-PEG IgM induction and on the accelerated clearance of PEGylated liposomes","volume":"127","author":"Shimizu","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2023.01.021_bb0165","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1158\/1535-7163.MCT-15-0151","article-title":"Selective delivery of PEGylated compounds to tumor cells by anti-PEG hybrid antibodies","volume":"14","author":"Tung","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jconrel.2023.01.021_bb0170","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1021\/bc100067t","article-title":"Sensitive quantification of PEGylated compounds by second-generation anti-poly(ethylene glycol) monoclonal antibodies","volume":"21","author":"Su","year":"2010","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2023.01.021_bb0175","doi-asserted-by":"crossref","first-page":"7808","DOI":"10.1021\/acsnano.9b07218","article-title":"Premature drug release from polyethylene glycol (PEG)-coated liposomal doxorubicin via formation of the membrane attack complex","volume":"14","author":"Chen","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2023.01.021_bb0180","doi-asserted-by":"crossref","first-page":"933","DOI":"10.2967\/jnumed.109.071977","article-title":"Development of a universal anti\u2013polyethylene glycol reporter gene for noninvasive imaging of PEGylated probes","volume":"51","author":"Chuang","year":"2010","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2023.01.021_bb0185","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/0003-2697(86)90520-8","article-title":"A fluorometric assay of the degree of modification of protein primary amines with polyethylene glycol","volume":"154","author":"Stocks","year":"1986","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.jconrel.2023.01.021_bb0190","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s002620050387","article-title":"Poly(ethylene glycol) modification of beta-glucuronidase-antibody conjugates for solid-tumor therapy by targeted activation of glucuronide prodrugs","volume":"44","author":"Cheng","year":"1997","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.jconrel.2023.01.021_bb0195","series-title":"Methods in Enzymology","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/0076-6879(90)82056-8","article-title":"[54] radiolabeling of proteins","author":"Parker","year":"1990"},{"key":"10.1016\/j.jconrel.2023.01.021_bb0200","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1002\/bmc.1054","article-title":"Improved HPLC method for doxorubicin quantification in rat plasma to study the pharmacokinetics of micelle-encapsulated and liposome-encapsulated doxorubicin formulations","volume":"22","author":"Wei","year":"2008","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jconrel.2023.01.021_bb0205","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0378-4347(98)00475-7","article-title":"High-performance liquid chromatographic validated assay of doxorubicin in rat plasma and tissues","volume":"721","author":"Alvarez-Cedr\u00f3n","year":"1999","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"10.1016\/j.jconrel.2023.01.021_bb0210","series-title":"Isolation of liver Kupffer cells, Curr Protoc Toxicol, Chapter 14","author":"Froh","year":"2003"},{"key":"10.1016\/j.jconrel.2023.01.021_bb0215","doi-asserted-by":"crossref","first-page":"2.9.1-8","DOI":"10.1002\/0471143030.cb0209s65","article-title":"Standardized isolation and culture of murine liver sinusoidal endothelial cells","volume":"65","author":"Cheluvappa","year":"2014","journal-title":"Curr Protoc Cell Biol"},{"key":"10.1016\/j.jconrel.2023.01.021_bb0220","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1177\/0192623314526475","article-title":"Formation, clearance, deposition, pathogenicity, and identification of biopharmaceutical-related immune complexes: review and case studies","volume":"42","author":"Rojko","year":"2014","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.jconrel.2023.01.021_bb0225","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/ki.1989.83","article-title":"Physiological and pathological aspects of circulating immune complexes","volume":"35","author":"Schifferli","year":"1989","journal-title":"Kidney Int."},{"key":"10.1016\/j.jconrel.2023.01.021_bb0230","doi-asserted-by":"crossref","first-page":"4613","DOI":"10.4049\/jimmunol.144.12.4613","article-title":"A study of in vivo immune complex formation and clearance in man","volume":"144","author":"Davies","year":"1990","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2023.01.021_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112502","article-title":"Impact of anti-PEG antibody affinity on accelerated blood clearance of pegylated epoetin beta in mice","volume":"146","author":"Chang","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.jconrel.2023.01.021_bb0240","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1080\/19420862.2018.1424610","article-title":"Development and characterization of an anti-rituximab monoclonal antibody panel","volume":"10","author":"Tada","year":"2018","journal-title":"MAbs"},{"key":"10.1016\/j.jconrel.2023.01.021_bb0245","doi-asserted-by":"crossref","first-page":"4981","DOI":"10.4049\/jimmunol.1202017","article-title":"Fc\u03b3RIIb on liver sinusoidal endothelium clears small immune complexes","volume":"189","author":"Ganesan","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2023.01.021_bb0250","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/nmat4718","article-title":"Mechanism of hard-nanomaterial clearance by the liver","volume":"15","author":"Tsoi","year":"2016","journal-title":"Nat. Mater."},{"key":"10.1016\/j.jconrel.2023.01.021_bb0255","doi-asserted-by":"crossref","first-page":"16014","DOI":"10.1038\/natrevmats.2016.14","article-title":"Analysis of nanoparticle delivery to tumours","volume":"1","author":"Wilhelm","year":"2016","journal-title":"Nature Reviews Materials"},{"key":"10.1016\/j.jconrel.2023.01.021_bb0260","series-title":"Allergy frontiers: classification and pathomechanisms","first-page":"79","article-title":"Immune complexes: Normal physiology and role in disease","author":"Frank","year":"2009"},{"key":"10.1016\/j.jconrel.2023.01.021_bb0265","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1517\/14728214.2015.1113254","article-title":"What is the future of PEGylated therapies?","volume":"20","author":"Swierczewska","year":"2015","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1016\/j.jconrel.2023.01.021_bb0270","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.xphs.2015.11.015","article-title":"PEGylation of biopharmaceuticals: a review of chemistry and nonclinical safety information of approved drugs","volume":"105","author":"Turecek","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2023.01.021_bb0275","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12929-019-0589-7","article-title":"Structural basis of polyethylene glycol recognition by antibody","volume":"27","author":"Lee","year":"2020","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.jconrel.2023.01.021_bb0280","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/s42004-020-00369-y","article-title":"Structure of an anti-PEG antibody reveals an open ring that captures highly flexible PEG polymers","volume":"3","author":"Huckaby","year":"2020","journal-title":"Communications Chemistry"},{"key":"10.1016\/j.jconrel.2023.01.021_bb0285","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jconrel.2018.06.002","article-title":"A minimal physiologically based pharmacokinetic model that predicts anti-PEG IgG-mediated clearance of PEGylated drugs in human and mouse","volume":"284","author":"McSweeney","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.01.021_bb0290","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1124\/jpet.104.079277","article-title":"Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys","volume":"313","author":"Rojas","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jconrel.2023.01.021_bb0295","doi-asserted-by":"crossref","first-page":"15191","DOI":"10.1021\/acsnano.1c05713","article-title":"Density of conjugated antibody determines the extent of fc receptor dependent capture of nanoparticles by liver sinusoidal endothelial cells","volume":"15","author":"Kappel","year":"2021","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2023.01.021_bb0300","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jconrel.2016.01.020","article-title":"Nanoparticle-liver interactions: cellular uptake and hepatobiliary elimination","volume":"240","author":"Zhang","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.01.021_bb0305","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0022-1759(94)90012-4","article-title":"Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications","volume":"174","author":"Van Rooijen","year":"1994","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jconrel.2023.01.021_bb0310","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/hep.21748","article-title":"Receptor-mediated endocytosis of immune complexes in rat liver sinusoidal endothelial cells is mediated by FcgammaRIIb2","volume":"46","author":"Mousavi","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jconrel.2023.01.021_bb0315","doi-asserted-by":"crossref","first-page":"873","DOI":"10.3389\/fphys.2020.00873","article-title":"Prominent receptors of liver sinusoidal endothelial cells in liver homeostasis and disease","volume":"11","author":"Pandey","year":"2020","journal-title":"Front. Physiol."},{"key":"10.1016\/j.jconrel.2023.01.021_bb0320","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jconrel.2018.08.022","article-title":"Anti-polyethylene glycol antibodies alter the protein corona deposited on nanoparticles and the physiological pathways regulating their fate in vivo","volume":"287","author":"Grenier","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.01.021_bb0325","series-title":"Chapter 12 \u2013 Abnormalities in Immune Complex Clearance and Fc\u03b3 Receptor Function","author":"Salmon","year":"2013"},{"key":"10.1016\/j.jconrel.2023.01.021_bb0330","series-title":"Primer to the Immune Response","first-page":"55","article-title":"Chapter 3 - innate immunity","year":"2014"},{"key":"10.1016\/j.jconrel.2023.01.021_bb0335","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.624025","article-title":"Complement receptors and their role in leukocyte recruitment and phagocytosis","volume":"9","author":"Vandendriessche","year":"2021","journal-title":"Frontiers in Cell and Developmental Biology"},{"key":"10.1016\/j.jconrel.2023.01.021_bb0340","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s12860-020-00331-9","article-title":"Transcriptome and proteome profiling reveal complementary scavenger and immune features of rat liver sinusoidal endothelial cells and liver macrophages","volume":"21","author":"Bhandari","year":"2020","journal-title":"BMC Molecular and Cell Biology"},{"key":"10.1016\/j.jconrel.2023.01.021_bb0345","doi-asserted-by":"crossref","DOI":"10.3390\/cells9051227","article-title":"Liver sinusoidal endothelial cells contribute to hepatic antigen-presenting cell function and Th17 expansion in cirrhosis","volume":"9","author":"Caparr\u00f3s","year":"2020","journal-title":"Cells"},{"issue":"8","key":"10.1016\/j.jconrel.2023.01.021_bb0350","doi-asserted-by":"crossref","first-page":"11769","DOI":"10.1021\/acsnano.2c04543","article-title":"Anti-PEG antibodies boosted in humans by SARS-CoV-2 lipid nanoparticle mRNA vaccine","volume":"16","author":"Ju","year":"2022","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2023.01.021_bb0355","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23168838","article-title":"Monitoring anti-PEG antibodies level upon repeated lipid nanoparticle-based COVID-19 vaccine administration","volume":"23","author":"Guerrini","year":"2022","journal-title":"Int. J. Mol. Sci."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365923000226?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365923000226?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:37:03Z","timestamp":1759163823000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365923000226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":71,"alternative-id":["S0168365923000226"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.01.021","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Accelerated clearance by antibodies against methoxy PEG depends on pegylation architecture","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.01.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}